A New Approach to Targeting Tau in Alzheimer’s Disease by Inhibiting Its Interaction With Fyn

Erik Roberson, MD, PhD
University of Alabama at Birmingham (Birmingham, AL)

Co-Principal Investigators

Corinne Augelli-Szafran, PhD
University of Alabama at Birmingham (Birmingham, AL)
Year Awarded:
2015
Grant Duration:
July 1, 2015 to June 30, 2018
Disease:
Alzheimer's Disease
Award Amount:
$250,000
Grant Reference ID:
A2015693S
Award Type:
Standard
Award Region:
US Southern

This grant is made possible in part by a grant from the Jerome Jacobson Foundation.

Development of Inhibitors of the Tau-Fyn Interaction for the Treatment of Alzheimer's Disease

Summary

The purpose of this project is to identify a novel therapy for treating Alzheimer's disease (AD). We are investigating compounds that would stop the interaction between two proteins, tau and Fyn. Considerable data indicates that blocking this interaction could ameliorate AD.

Details

Tau is widely considered an excellent target for AD, but it is unclear how to target it. Normal tau serves a physiologic role in humans, including to stabilize microtubule structures that are important for transporting molecules throughout the neuron. However, while we know that tau is involved in Alzheimer’s disease, we don’t yet know exactly how tau contributes. A variety of data indicate that Tau’s interaction with another protein known as Fyn tyrosine kinase may be critical. Tau and Fyn bind with each other, and we and others have obtained a variety of data indicating that Fyn is involved in AD.  We are investigating compounds that would stop the interaction between tau and Fyn.  We set out to develop inhibitors of the tau-Fyn interaction and screened approximately 100,000 compounds to identify several "hits" that block the interaction. The next phase of the project is to further evaluate and refine these hits to develop lead compounds for evaluation in animal models. If successful, this work could help identify a new therapeutic approach to AD. 

About the Researcher

Erik Roberson, MD, PhD, is an associate professor of neurology and neurobiology and co-director of the Center for Neurodegeneration and Experimental Therapeutics at the University of Alabama at Birmingham (UAB). He received his bachelor’s degree with highest honors from Princeton University and then earned his MD and PhD in neuroscience at Baylor College of Medicine, where he studied molecular mechanisms of learning and memory. He completed a residency in neurology at the University of California, San Francisco (UCSF), where he also served as chief resident in neurology. After residency, he completed a clinical fellowship in behavioral neurology with Bruce Miller, MD, at UCSF and resumed basic research in the laboratory of Dr. Lennart Mucke, MD, at the Gladstone Institute of Neurological Disease, UCSF, initiating his current studies of neurodegenerative disease using mouse models. He joined the neurology faculty at UCSF in 2005, then moved to UAB in 2008. The Roberson lab studies the neurobiology of AD and frontotemporal dementia (FTD), with a focus on understanding the cellular and molecular mechanisms of these disorders and identifying new therapeutic strategies. The role of tau in neuronal dysfunction in AD and FTD is a major area of interest, and the lab also studies how progranulin deficiency causes FTD.  In addition to directing his laboratory, Dr. Roberson co-director of the Center for Neurodegeneration and Experimental Therapeutics, which is dedicated to developing new therapies for age-related cognitive disorders and neurodegenerative disease. Dr. Roberson also cares for patients with memory disorders and dementia at the Kirklin Clinic and directs clinical trials related to tauopathies.



"As a physician-scientist, I am committed to translating basic science discoveries about AD as far as possible toward therapies. This work started about 10 years ago when we found that reducing tau in mouse models was protective. We reasoned that reducing tau in people would be difficult, so instead we have looked for a way to reduce the aberrant form of tau which, of course, remains somewhat of a mystery.  Over the years, we have accumulated evidence that tau’s interaction with Fyn is important, so we started this drug discovery/development project to pursue a new therapeutic approach involving this pathway."

Don't miss out.
Receive research updates, inspiring stories, and expert advice
Keep me informed about: *
Please select at least one.
You must select at least one disease category.
Please enter your first name.
Please enter your last name.